Status:
COMPLETED
Impact of Systemic Corticosteroid Therapy on Lens Transparency and Quantification of Lens Autofluorescence.
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adver...
Detailed Description
Corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adver...
Eligibility Criteria
Inclusion
- Patient who starts a treatment with Prednisone, Prednisolone or Methylprednisolone for an Expected time of one year at least, with normal lens autofluorescence at inclusion.
Exclusion
- Previous cataracts and abnormal increase of lens autofluorescence considering age
- Previous elevation of intraocular pressure
- Progressive inflammatory or non inflammatory ocular disease
- Eye drop except artificial tears
- Insulin dependent and non insulin dependent diabetes
- Atopic dermatitis
- Previous protracted corticosteroid therapy
- Drugs known to be associated with an increased risk of cataract
Key Trial Info
Start Date :
June 1 2000
Trial Type :
INTERVENTIONAL
End Date :
July 1 2006
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00337623
Start Date
June 1 2000
End Date
July 1 2006
Last Update
June 23 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clermont-Ferrand University Hospital
Clermont-Ferrand, Auvergne, France, 63003